The report provides a detailed analysis essential for establishing a Trastuzumab production plant. It encompasses all critical aspects necessary for Trastuzumab production, including the cost of Trastuzumab production, Trastuzumab plant cost, Trastuzumab production costs, and the overall Trastuzumab production plant cost. Additionally, the study covers specific expenditures associated with setting up and operating a Trastuzumab production plant. These encompass production processes, raw material requirements, utility requirements, infrastructure needs, machinery and technology requirements, manpower requirements, packaging requirements, transportation requirements, and more.
Trastuzumab is a monoclonal antibody that has an important role in the treatment of certain types of cancer, namely breast, stomach, and esophageal cancers. It is precisely devised to target and bind to the HER2 receptor, which is prominent in approximately 20-30% of breast cancers and gastric and gastroesophageal cancers. It has shown significant improvement in survival and reduced the risk of cancer recurrence by hindering the multiplication of these HER2-positive tumor cells and facilitating antibody-dependent cellular cytotoxicity when used with chemotherapy or hormone blockers.
Trastuzumab has therapeutic applications in the treatment of HER2-positive metastatic breast cancer, early-stage HER2-positive breast cancer, and HER2-positive metastatic stomach cancer. Its exceptional clinical efficacy had a transformative impact on the management of these HER2-driven malignant cells, making it a critical component of modern oncology treatment.
The key driving factor in Trastuzumab procurement is its significant role in the treatment of certain types of cancer. Trastuzumab has shown significant improvements in patients with HER2-positive breast, stomach, and esophageal cancers when used in combination with chemotherapy or hormone blockers, making it an essential component of modern oncology treatment. The drug is precisely designed to target and bind to the HER2 receptor, and its exceptional clinical efficacy has had a transformative impact on the management of HER2-driven cancers.
Trastuzumab biosimilar version production has the potential to increase access and affordability, further driving the demand for this life-saving treatment. Hence, Trastuzumab's exceptional performance in treating various types of cancer, along with its production prices, market prices, and logistics, directly influences industrial Trastuzumab procurement in the market across the globe.
Raw Material for Trastuzumab Production
According to the Trastuzumab production plant project report, the key raw materials used in the production of Trastuzumab include CHO (Chinese Hamster Ovary) cells-cell culture media-formulation excipients.
Production Process of Trastuzumab
The detailed Trastuzumab production cost report consists of the following major industrial production processes:
- From CHO cells, the genetic construct, and formulation excipients: The production process of Trastuzumab begins with genetically engineered Chinese Hamster Ovary (CHO) cells. A tricistronic vector containing the genes for the heavy chain, light chain, and a selection marker is introduced in the CHO cells that results in antibody production. The modified CHO cells are grown in large bioreactors to produce the Trastuzumab. The culture fluid is made to go through centrifugation, filtration, and chromatography to obtain and purify the antibody. The purified Trastuzumab is then formulated, filled into vials, and freezed to create the final drug product.
Trastuzumab is formulated as a lyophilized powder, white to slightly yellow in. In liquid form, it has a pH range of 5.4 to 6.6 and an approximate molecular weight of 148 kDa, having 1,328 amino. It does not contain any antimicrobial preservatives, ensuring the safety and efficacy of the drug. Still, it is essential to avoid diluting trastuzumab with glucose solutions, as this can lead to aggregation and potentially impact its biological activities. Trastuzumab's physical and chemical, along with its clinical efficacy, have contributed to its widespread use in the management of HER2-driven cancers.
